Stock Quote
Bioheart, Inc. (BHRT.OB) (OTC BB)
$0.80
2:38pm EST
-10.11%
$0.89
$0.89
4,550
$0.89
$0.80
$2.50
$0.30
0.16
11,696
No news stories for this company within the last 30 days.
BHRT.OB
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Groth, Karl | Chairman of the Board, Chief Executive Officer | -- |
| Borman, Mark | Chief Financial Officer, Director | -- |
| Farley, Peggy | Chief Operating Officer, Director | -- |
Profile
Bioheart, Inc. is a biotechnology company focused on the discovery, development and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic acute heart damage and peripheral vascular disease. MyoCell is a clinical therapy designed to populate... Full Description
Company Address
Bioheart, Inc.
13794 NW 4th Street
Suite 212
Sunrise FL 33325
P: +1954.8351500
F: +1954.8459976
13794 NW 4th Street
Suite 212
Sunrise FL 33325
P: +1954.8351500
F: +1954.8459976
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Medtronic, Inc. | $40.21 | +0.59 |
| Baxter International Inc. | $54.60 | +0.27 |
| St. Jude Medical, Inc. | $34.97 | +0.65 |
| BHRT.OB | Industry | |
|---|---|---|
| P/E(TTM) | -- | 12.80 |
| P/S(TTM) | 64.83 | 29.90 |
| ROI(TTM) | -- | 2.35 |
| ROE(TTM) | -- | 3.59 |
No consensus estimates data available.
| Total Revenue | $0.10M |
| Net Income | $-1.67M |
| EPS | $-0.10 |
